Ajanta Pharma has received final approval for Omeprazole and Sodium Bicarbonate Powder for Oral Suspension from USFDA. It is a bioequivalent generic version of Zegerid Powder for Oral Suspension and the company will be launching the product soon in 2 strengths 20 mg / 1680 mg & 40 mg / 1680 mg Powder Sachets.
This new approval is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 12 ANDAs; tentative approvals for 1 ANDA; and 13 ANDAs are under review with USFDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. The company is engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: